GIP and type 2 diabetes mellitus: Although compounds that display dual GIP and GLP-1 receptor agonism appear to be more effective for weight loss and glycaemic control than the GLP-1 receptor agonists, liraglutide and dulaglutide, in patients with T2DM [96,97], the relative contribution of GIP signalling to this superiority remains to be characterized in humans.